Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

Conditions: Relapsed/Refractory Mantle Cell Lymphoma; Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia Interventions: Drug: KTE-X19; Drug: Cyclophosphamide; Drug: Fludarabine Sponsors: Kite, A Gilead Company Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials